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GENETIC TESTING PRACTICES OF GENETIC COUNSELORS, GENETICISTS, AND PEDIATRIC
NEUROLOGISTS WITH REGARD TO CHILDHOOD-ONSET NEUROGENETIC CONDITIONS

Sara Christine Wofford, B.S.

Advisory Professor: Sarah Noblin, M.S., CGC

Identifying genetic diagnoses for neurological conditions with a considerable hereditary
component, such as autism spectrum disorder (ASD), intellectual disability, and epilepsy, is
critical to providing proper medical management for these patients and their families.
However, many patients with these conditions are not tested appropriately or receive no
genetic testing at all (1). The current study was designed to characterize the genetic testing
practices of the providers most likely to evaluate or order genetic testing for these patients:
pediatric neurologists, geneticists, and genetic counselors. The study noted significant variance
between the testing strategies selected by pediatric neurologists compared to those of
geneticists and genetic counselors and supports the need for updated guidelines that are
consistent across specialties. Pediatric neurologists report lower confidence with ordering
genetic testing and a need and desire for further education regarding genetic testing. This study
proposes that the continued integration of genetic counselors into pediatric neurology clinics
may improve utilization of genetic testing while reducing the burden on neurologists.
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Introduction
Many neurological conditions identified in childhood, such as autism spectrum disorder
(ASD), epilepsy, and intellectual disability have a significant genetic component. Approximately
1% of children living in the United States have ASD and 10% of those cases are due to an
underlying genetic disorder, such as Fragile X syndrome (FXS) (2-5). Similarly, approximately 1%
of the United States population has epilepsy and up to 3% of individuals with epilepsy have a
genetic form (6, 7). Intellectual disability is found in approximately 1-3% of individuals, and,
depending on the severity of the delay, 25-50% of those cases are related to a genetic
abnormality(8). Given the significant chance of identifying a genetic etiology in many common
childhood-onset neurological conditions, genetic testing offers considerable value to patients
with these disorders, not only for diagnostic purposes, but also to determine if other specialty
evaluations and treatments are indicated or if additional family members may have health or
reproductive implications. For example, patients with ASD related to FXS should be screened
for cardiac abnormalities and their family members may require evaluation for FXS or related
health concerns. These recommendations differ greatly from those typically made for children
with non-syndromic ASD (9).Therefore, children with ASD who do not receive testing for FXS
may be missing necessary medical treatments and evaluations.
Proper utilization of genetic testing involves not only patients receiving testing when
indicated, but also the selection of the best testing strategy for a particular indication.
Unfortunately, previous literature suggests many individuals with neurological conditions that
warrant genetic testing do not receive recommended testing (1). Approximately 68% of
1

children with ASD do not receive any genetic testing despite current recommendations (1). For
patients with ASD, the 2013 ACMG guidelines recommend chromosomal microarray (CMA) and
FXS analysis. However, the most recent Child Neurology Society Guidelines for the screening
and diagnosis of ASD recommends karyotyping and FXS analysis (10, 11). Notably, CMA was not
used in clinical practice in 2000, the time of this publication. A similar pattern is seen for
patients with unexplained intellectual disability. The American Academy of Pediatrics (AAP),
American Academy of Neurology and American College of Medical Genetics and Genomics
(ACMG) recommend CMA and FXS analysis as first-tier testing (12-14). By contrast, the relevant
Child Neurology Society Guidelines from 2000, last updated in 2010, recommend karyotype
analysis in addition to FXS analysis. Currently, there are no professional guidelines outlining
proper genetic testing practices for patients with epilepsy. The variation in recommendations
across specialties for these neurological conditions may present an obstacle to patients
receiving recommended testing and appropriate medical care.
In order to address the issue of proper utilization of genetic testing for patients with
neurological conditions, it is necessary to gather data about the genetic testing practices of the
practitioners that most commonly participate in ordering their genetic testing. The purpose of
this study was to compare the attitudes and practices of pediatric neurologists, medical
geneticists, and genetic counselors regarding genetic testing for pediatric patients with
neurological conditions. Through doing so, this study aimed to identify where these providers
differ in their utilization of genetic testing with the goal of informing plans to increase
consistent and appropriate utilization of genetic testing for this patient population.
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Methods
Study Design
This was a cross-sectional study utilizing an electronic survey to assess the genetic
testing practices of genetic counselors, geneticists, and pediatric neurologists. Approval of this
study was granted by the Institutional Review Board at The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical Sciences (IRB Number: HSC-GSBS-170695).
Genetic counselors, medical geneticists, and pediatric neurologists that are boardcertified in their field, see patients with neurological conditions at least once per month, and
have ordered genetic testing within the last six months met the inclusion criteria for this study.
Participants were contacted electronically, either personally or through the listserv of their
respective professional organization. Genetic counselors were recruited from the National
Society of Genetic Counselors via an initial electronic mail message and a follow up reminder
three weeks later; while pediatric neurologists were contacted via the Child Neurology Society
(CNS) listserv through a single electronic mail message. Medical geneticists were contacted by
two personal electronic mail messages informing them of the option to participate in this study.
Responses were collected over a period of approximately three months between September
22, 2017 and December 10, 2017.
Instrumentation
The instrumentation used in this study was an investigator-designed, non-validated
questionnaire hosted on Qualtrics®, an online survey software. All participants took the survey
3

online and their responses remained anonymous. Participants had the option to participate in a
random drawing for one of two available gift cards by providing contact information that was
not linked to the individual’s survey responses.
The survey was divided into five sections: assessment of genetic testing utilization (11
items), scoring of factors considered when deciding on a genetic testing strategy (4 items),
assessment of testing practice for common indications (4 items), self-reported knowledge
assessment of genetics topics (4 items), and demographic information (5 items). It was optional
to answer each question. Question types included single choice, visual analog scale (VAS), and
Likert scales (see appendix 1). The survey instrument was created specifically for this project
and was reviewed for clarity and consistency by the authors. The instrument was not validated.
Data Analysis
Data from Qualtrics was imported in STATA (v.13.0, College Station, TX) for analysis.
Categorical variables are described using frequencies and percentages. Continuous variables
were not normally distributed and are described using medians and interquartile ranges (IQR).
Comparison between clinician groups were made using contingency tests (chi-square or Fisher
exact) for categorical variables and using Kruskal-Wallis test with a post-hoc Dunn’s test for
continuous variables. Comparison of data between groups was evaluated using descriptive
analysis. Statistical significance was assumed at a Type I error rate of 5%.
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Results
Respondent Demographics
Of the 397 individuals who opened the survey, 251 submitted a completed survey and
met the inclusion criteria. Those responses included 103 genetic counselors, 35 geneticists, and
113 pediatric neurologists (Figure 1).

Figure 1:Responses flowchart describing inclusion and exclusion criteria

Of the 251 respondents, 51% reported working in their field for 5 or fewer years, though
this rate is highest among genetic counselors, at 79% (p<0.001). Genetic counselor respondents
5

were significantly more likely to be female (93%) than geneticist (61%) or pediatric neurologist
respondents (48%) (p<0.001).

Genetic Counselor
n (%)

Geneticist
n (%)

Neurologist
n (%)

Total
n (%)

7 (7)

12 (36)

52 (51)

71 (31)

87 (93)

20 (61)

49 (48)

156 (68)

0 (0)

1 (3)

1 (1)

2 (1)

22-25

20 (22)

0 (0)

0 (0)

20 (9)

26-30

42 (45)

0 (0)

2 (2)

44 (20)

31-40

22 (24)

11 (34)

44 (44)

77 (34)

41-50

4 (4)

10 (31)

28 (28)

42 (19)

51-60

4 (4)

6 (19)

12 (12)

22 (10)

>60

1 (1)

5 (16)

14 (14)

20 (9)

Sex
Male
Female
Other
Age

Years Working in Specialty
<1

13 (14)

1 (3)

2 (2)

16 (7)

1-5

60 (65)

6 (19)

33 (33)

99 (44)

6-10

10 (11)

8 (25)

25 (25)

43 (19)

11-20

6 (6)

8 (25)

18 (18)

32 (14)

21-30

3 (3)

5 (16)

11 (11)

19 (8)

>30

1 (1)

4 (13)

12 (12)

17 (8)

<200

10 (11)

3 (9)

1 (1)

14 (6)

201-500

15 (16)

4 (13)

18 (18)

37 (16)

501-1000

14 (15)

5 (16)

17 (17)

36 (16)

1001-3000

11 (12)

8 (25)

20 (20)

39 (17)

>3000
Not Sure

10 (11)

7 (22)

28 (28)

45 (20)

33 (35)

6 (19)

17 (17)

56 (25)

Active Patients at Practice

Patient Insurance
Predominantly Private

25 (27)

3 (10)

20 (21)

48 (22)

Predominantly Medicaid

31 (34)

15 (48)

40 (42)

86 (39)

2 (2)

0 (0)

2 (2)

4 (2)

13 (42)

33 (35)

80 (37)

Predominantly Military

Mixed
34 (37)
Table 1: Demographic information of respondents
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Genetic Test Ordering Practices
When asked about genetic testing practices, there was no difference in the number of
genetic tests ordered in the past month between genetic counselors (median: 12, IQR: 5-20)
and geneticists (median: 12, IQR: 8-25). However, neurologists reported a significantly lower
number of tests ordered (median: 6, IQR: 4-10; p<0.001 for both). The respondents were also
asked about the types of genetic testing that they have ordered in the last six months.
Neurologists were found to be significantly less likely to order whole exome sequencing
(p<0.001) compared to geneticists or genetic counselors. Genetic counselors are less likely to
order or assist in ordering chromosome microarray than the other respondents (p=<0.001).
Testing Strategies for Common Neurological Conditions
Respondents selected the genetic test or tests they would order as first-tier testing for a
patient with an isolated neurological condition (Table 2). Overall, genetic counselor and
geneticist responses were not significantly different. However, many of the testing plans
selected by the neurologists varied significantly from those chosen by the geneticists, genetic
counselors, or both.
Autism with Intellectual Disability: Respondents were most likely to select CMA and FXS
analysis for the first line of testing they would offer to a patient with this indication (93% and
84%, respectively). Only 2% of respondents overall selected that they would order no testing
for this indication. Neurologists were significantly less likely to order Fragile X analysis than
genetic counselors (p=0.041), less likely to order whole exome sequencing than genetic
7

counselors and geneticists (p=0.002), but more likely to order a karyotype for this indication
(p=0.020). Most respondents (71%) included both tests currently recommended for first-tier
testing, chromosome microarray and Fragile X analysis. Forty-eight percent of all respondents
selected only these two tests. Of the respondents who selected CMA and Fragile X analysis for a
patient with ASD and intellectual disability, 13.5% also reported that they would also order
whole exome sequencing as a first line test for this patient. Within that same group, 22%
reported they would order a karyotype in addition to a CMA and Fragile X analysis (12% of
genetic counselors, 12 % of geneticists, and 27% of neurologists overall).
Autism without Intellectual Disability (isolated ASD): CMA and Fragile X analysis were
the most selected tests for this indication (73% and 51% respectively). Overall, 17% of
respondents indicated that they are unsure of what testing to order, or their decision depends
on additional information. Twenty-six percent of neurologists responded that they would not
order any testing for isolated ASD, significantly more than genetic counselors or geneticists
(p<0.001). Forty-nine percent of respondents included both chromosome microarray and
Fragile X analysis when testing a patient with isolated ASD, and 33% selected those two tests
exclusively.
Intellectual Disability: CMA and Fragile X analysis were again the most selected tests for
intellectual disability (88% and 60%, respectively). Sixteen percent of respondents reported that
they did not know what testing they would choose, or that the decision would depend on
additional information. In this case, neurologists were more likely to select that they would not
order any testing (p=0.046), and less likely to choose CMA (p=0.001), Fragile X analysis
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(p=0.007), or whole exome sequencing (p<0.001) for patients with intellectual disability. The
respondents were most likely to select a combination of Fragile X and CMA when presented
with a patient with isolated intellectual disability (29.1%).
Epilepsy: The tests most likely to be selected to evaluate epilepsy were panel gene
sequencing for related genes and CMA (63% and 41%, respectively). Approximately 28% of
respondents reported that they were unsure of the testing they would order or would require
more information. Neurologists were significantly more likely to report that they are
unsure/require more information (p<0.001). Neurologists were less likely to order a CMA
(p<0.001) or whole exome sequencing (p=0.002) than other respondents. For patients
presenting with epilepsy, respondents were most likely to select panel testing alone (27.1%) or
panel testing with CMA (13.6%) as their first-tier testing plan.
Behavioral Problems: The respondents were most likely to select that they would not
order any genetic testing for this condition (49%). The respondents who would order testing
most commonly chose CMA (23%) or Fragile X analysis (13%). Neurologists were significantly
more likely to select that they would order no testing (p<0.001) and less likely to choose CMA
(p<0.001) or Fragile X analysis (p<0.001).
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Genetic Counselor
n (%)
N = 94

Geneticist
n (%)
N = 33

Neurologist
n (%)
N = 103

Total
n (%)
N = 230

I would not order any testing

1 (1)

0 (0)

4 (4)

5 (2)

Chromosome microarray

90 (96)

32 (97)

93 (90)

215 (93)

Fragile X testing (FMR1 analysis)

85 (90)

29 (88)

80 (78)

194 (84)

Whole exome sequencing

19 (20)

6 (18)

4 (4) †*

29 (13)

Panel gene sequencing for related genes

11 (12)

2 (6)

9 (9)

22 (10)

Single gene sequencing

1 (1)

1 (3)

0 (0)

2 (1)

Karyotype/Chromosome analysis
I don't know/it depends on other
information

12 (13)

4 (12)

28 (27) †*

44 (19)

10 (11)

3 (9)

11 (11)

24 (10)

I would not order any testing

6 (6)

1 (3)

27 (26) †*

34 (15)

Chromosome microarray

78 (83)

30 (91)

59 (57) †*

167 (73)

Fragile X testing (FMR1 analysis)

61 (65)

18 (55)

39 (38) †*

118 (51)

Whole exome sequencing

9 (10)

1 (3)

2 (2)

12 (5)

Panel gene sequencing for related genes

6 (6)

2 (6)

2 (2)

10 (4)

Single gene sequencing

1 (1)

1 (3)

1 (1)

3 (1)

Karyotype/Chromosome analysis
I don't know/it depends on other
information

9 (10)

4 (12)

9 (9)

22 (10)

19 (20)

3 (9)

18 (17)

40 (17)

I would not order any testing

2 (2)

0 (0)

6 (6) †*

8 (3)

Chromosome microarray

52 (56)

18 (55)

24 (24) †*

94 (41)

Fragile X testing (FMR1 analysis)

5 (5)

3 (9)

1 (1)

9 (4)

Whole exome sequencing

16 (17)

8 (24)

4 (4) †*

28 (12)

Panel gene sequencing for related genes

67 (72)

19 (58)

56 (55)

142 (62)

Single gene sequencing

2 (2)

0 (0)

4 (4)

6 (3)

Karyotype/Chromosome analysis
I don't know/it depends on other
information

6 (6)

1 (3)

1 (1)

8 (3)

18 (19)

3 (9)

42 (41) †*

63 (27)

Autism with intellectual disability

Autism without intellectual disability

Epilepsy**
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Intellectual disability
I would not order any testing

1 (1)

0 (0)

7 (0) †*

8 (3)

Chromosome microarray

87 (93)

30 (91)

76 (73) †*

193 (84)

Fragile X testing (FMR1 analysis)

67 (71)

21 (64)

51 (50) *

139 (60)

Whole exome sequencing

16 (17)

9 (27)

2 (2) †*

27 (12)

Panel gene sequencing for related genes

20 (21)

3 (9)

7 (7) *

30 (13)

Single gene sequencing

1 (1)

0 (0)

0 (0)

1 (0)

Karyotype/Chromosome analysis
I don't know/it depends on other
information

10 (11)

3 (9)

16 (16)

29 (13)

11 (12)

3 (9)

23 (22)

37 (16)

Behavioral problems***

8 (3)

I would not order any testing

37 (39)

8 (24)

66 (65) †*

111 (48)

Chromosome microarray

30 (32)

14 (42)

8 (8) †*

52 (23)

Fragile X testing (FMR1 analysis)

21 (22)

5 (15)

3 (3) †*

29 (13)

Whole exome sequencing

1 (1)

0 (0)

0 (0)

1 (0)

Panel gene sequencing for related genes

5 (5)

0 (0)

0 (0) *

5 (2)

Single gene sequencing

0 (0)

0 (0)

0 (0)

0 (0)

Karyotype/Chromosome analysis
3 (3)
1 (3)
3 (3)
I don't know/it depends on other
information
36 (38)
14 (42)
30 (30)
* denotes a statistically significant difference compared to Genetic Counselor response (p ≤ 0.05)
† denotes a statistically significant difference compared to Geneticist response (p ≤ 0.05)
** Genetic counselor N = 93, Neurologist N = 102
*** Neurologist N = 101

7 (3)
80 (35)

Table 2: First-line genetic tests selected for isolated neurological conditions.

Perceived Knowledge Assessment
Respondents rated their knowledge of topics related to neurogenetics (Table 3).
Neurologists rated themselves significantly lower than geneticists for knowledge of molecular
genetics (p<0.001) and testing guidelines for genetic neurological conditions (p=0.007), but
ranked themselves highest for knowledge of genetic neurological conditions.
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When asked about their confidence on topics related to ordering genetic tests for
patients, neurologists consistently reported the lowest levels of confidence. The statistical
significance of these ratings (scaled from 1 to 5, with 5 being the highest level of confidence),
are described below in Table 3. Neurologists reported significantly lower confidence on most
topics: knowing when to order genetic tests, choosing the most appropriate test for a patient,
interpreting test results, explaining test results to patients, and ordering tests to maximize
diagnostic power while minimizing cost (p<0.001 for all). Neurologists were not significantly
different from the other respondents with regard to their comfort handling the emotions that
arise during a results disclosure. Notably, genetic counselors were less confident in knowing
when to order genetic tests (p=0.001) and choosing the most appropriate test for a patient
(p=0.013) compared to geneticists.
A majority of neurologists responded yes when asked if they believed they would
significantly benefit from further training on topics related to genetic testing, such as knowing
when to order genetic tests, choosing the most appropriate test for a patient, interpreting test
results, explaining test results, handling emotions during a results disclosure, and ordering tests
to maximize diagnostic power and minimize costs (Table 3). A majority of genetic counselors
and geneticists responded no to these same questions.
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Genetic Counselor
N = 92

Geneticist
N = 33

Neurologist
N = 100

Self-Reported Knowledge (VAS 1-10), mean (SD)
Molecular Genetics

8.11 (1.62)

7.88 (1.80)

5.08 (2.43) †*

Neurological Genetic Conditions

6.8 (1.63)

7.18 (1.42)

7.28 (1.82) *

Testing Guidelines for Genetic Neurological
Conditions

6.71 (1.94)†

7.69 (1.71)*

6.51 (1.94) †

Confidence in Ability (VAS 1-5), mean (SD)
Knowing when to order genetic tests

4.23† (1.11)

4.67 (0.99)

4.17 (0.92) †

Choosing the most appropriate test for a patient

4.13 (1.07)†

4.48 (1.00)*

3.75 (0.95)†*

Interpreting test results

4.15 (1.06)

4.30 (0.92)

3.41 (1.08) †*

Explaining test results to patients

4.49 (1.03)

4.45 (1.00)

3.79 (1.02) †*

Handling emotions during result disclosure

4.22 (1.04)

4.24 (1.12)

3.94 (1.17) *

Ordering tests to maximize diagnostic power and
minimize cost

4.26 (1.08)

4.22 (1.01)

3.24 (1.16) †*

I would significantly benefit from more training
on…, n (%)
...When to order genetic testing

25 (27)

5 (15)

67 (71) †*

...How to interpret test results

23 (25)

9 (27)

72 (75) †*

...Counseling patients about genetic testing options

11 (12)

5 (15)

64 (67) †*

...Explaining genetic testing results to patients

12 (13)

3 (9)

64 (67) †*

* denotes a statistically significant difference compared to genetic counselor response (p ≤ 0.05)
† denotes a statistically significant difference compared to geneticist response (p ≤ 0.05)
Table 3: Self-rated knowledge and confidence regarding topics related to genetic testing for neurological conditions
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Discussion
Neurological conditions such as ASD, intellectual disability, and epilepsy have a
significant hereditary component that warrants genetic testing. This study was conducted to
characterize the genetic testing processes and practices of pediatric neurologists, geneticists,
and genetic counselors. These results show a lack of consistency between the clinicians
ordering genetic testing for pediatric neurological conditions and also identify areas where
further education and refinement of guidelines relevant to genetic testing for these conditions
would be valuable.
There is significant variance in the testing strategies selected by the responding
members of these three professions. For the majority of questions requiring the participants to
select a testing plan for an isolated condition, genetic counselors’ and geneticists’ responses
were not significantly different from each other but were significantly different from the
neurologists’ responses. Neurologists tended to be more likely to refrain from ordering testing,
particularly for patients with isolated ASD or epilepsy. They are less likely to order Fragile X
analysis for patients with ASD and/or intellectual disability and less likely to order chromosome
microarrays or gene panels for patients with epilepsy. These differences in practice could mean
that the genetic testing ordered for a patient is strongly influenced by whether their testing is
ordered by a genetics specialist or a neurologist. In the case of autism, providers who are not
ordering Fragile X for these patients are not providing a complete genetic evaluation, as
outlined by current professional guidelines, including those published by the American College
of Medical Genetics and Genomics (10). In addition, cases where providers are indicating that
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they would order testing that is not listed as a recommendation by a professional organization’s
guidelines may contribute to the over-ordering and improper use of genetic tests.
Current recommendations support ordering chromosome microarray and Fragile X
analysis as first-tier tests for patients with ASD. Although a majority of respondents overall
selected a testing plan in line with these recommendations, a significant number of
respondents did not include one or both of those tests in their testing strategy. Currently, there
are no professional guidelines for ordering genetic testing for patients with epilepsy published
by the AAP, ACMG, or CNS. As a result, respondents were more likely to respond “I don’t
know/it depends on other information” when asked about the testing they would order for a
patient with epilepsy. This data shows that genetic testing guidelines, where they exist, are
being followed inconsistently both within and across specialties. Some of the providers
selecting testing plans that differ from published guidelines may be acting upon new research
about genetic testing for neurological conditions released after the guidelines were published
(15, 16). Others may be referring to outdated information, such as those ordering karyotypes
rather than chromosome microarray for patients with ASD or intellectual disability.
Additionally, the inconsistencies observed in the testing strategies of respondents point to a
need for updated, collaborative guidelines that are accessible to and agreed upon by pediatric
neurologists, geneticists, and genetic counselors.
This study identified pediatric neurologists as candidates for further education and
training in ordering genetic testing, reflecting similar findings previously observed in
neurologists (17). Though pediatric neurologists have responsibilities that extend far beyond
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the scope of neurogenetics, the current trend towards increasing integration of genetics into
other medical specialties suggests that ordering genetic testing and interpreting genetic testing
results is a growing component of the medical management of patients being cared for by
pediatric neurologists. The pediatric neurologists who participated in this study reported that
they are receptive to and interested in further education about the proper clinical
implementation of genetic testing and believe that genetic testing is currently underutilized in
the field of neurology. For this reason, efforts to provide education about genetic testing to this
population would likely be well-received. Inclusion of more genetic counselors in neurology
clinics also may improve the utilization of genetic testing in these settings while limiting the
amount of further training that neurologists require to feel comfortable ordering genetic
testing for their patients. Genetic testing technology is rapidly evolving and many clinicians will
not be aware of the latest advancements, particularly those whose primary specialty is not
genetics. Genetic counselors in neurology clinics can stay apprised of guideline revisions and
shift this responsibility away from neurologists.
This study was limited in its statistical power by the comparatively few participating
medical geneticists. Unlike genetic counselors and neurologists, geneticists were not reachable
by listserv and were instead contacted personally. Additionally, the survey relied on selfreported data, which may not be an accurate representation of the respondent’s actual genetic
testing practices or knowledge of topics related to genetics. The survey tool used was not
validated. As such, there is potential for respondents to interpret questions differently than
intended.
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Future research should investigate methods for improving proper utilization of genetic
testing for pediatric neurology patients, including examining the feasibility of incorporating
more genetic counselors into pediatric neurology clinics and improving adherence to genetic
testing guidelines. Research that investigates the testing practices of these providers with their
actual patients via chart review would also add value to the field of pediatric neurology.
In conclusion, this research shows inconsistencies in the testing ordered for common
neurological conditions by neurologists, genetic counselors, and geneticists. Options exist to
address this variation in practice, such as writing collaborative, updated guidelines addressing
genetic testing for these conditions and incorporating genetic counselors and other genetics
specialists into pediatric neurology clinics.
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Appendix
Section 1 (Inclusion/Exclusion)
1. Which of the following best describes your job title?
a. Neurologist
b. Genetic Counselor
c. Geneticist
d. Other
2. (If job selected is Neurologist) Do you primarily see patients under the age of 18?
a. Yes
b. No
3. Do you see patients with neurological conditions (including developmental delay,
autism, seizures, etc.) at least once every month?
a. Yes
b. No
4. Are you board certified in your field?
a. Yes
b. No
Section 2
1. In the past 6 months, have you ordered/recommended genetic testing for a patient?
a. Yes
b. No
c. I don’t know
2. In the past month, approximately how many genetic tests for neurological conditions
have you ordered/recommended be ordered for your patients?
a. [Number entry]
3. For what percent of the patients you see is a genetic test ordered?
a. [Number entry – increments of 5]
4. Of the tests that you have ordered for your patients in the last 6 months, approximately
what percent of them were _____? Your answers should total 100.
a. WES [Number entry]
b. CMA [Number entry]
c. Gene panel sequencing test (e.g. Epilepsy Panel) [Number entry]
d. Methylation analysis (e.g. Angelman/Prader-Willi Methylation Testing) [Number
entry]
e. Triplet repeat expansion test (e.g. Fragile X Analysis) [Number entry]
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f. Single gene sequencing test (e.g. SCN1A Sequencing) [Number entry]
g. Other genetic test [Number entry]
5. In the past 6 months, have you ordered/recommended a genetic test be ordered for the
following conditions?
a. Muscular dystrophy
b. Neuropathy
c. Spinal muscular atrophy
d. Amyotrophic lateral sclerosis
e. Ataxia
f. Huntington Disease
g. Dystonia
h. Epilepsy
i. Other neurological disorders
6. (If job selected = neurologist or geneticist) Do you have access to a genetic counselor for
referrals?
a. Yes, we have one on our team
b. Yes, I have access to an external genetic counselor
c. No, I do not have access to a genetic counselor
d. I am not sure
7. In the past 6 months, approximately what percent of your new patients did you refer to
genetic counseling?
a. 0-10%
b. 11-20%
c. 21-30%
d. 31-40%
e. 41%-50%
f. 51%-60%
g. 61%-70%
h. 71%-80%
i. 81%-90%
j. 91%-100%
k. I do not refer patients to genetic counseling because a genetic counselor
regularly sees each patient at my practice by default
Section 3
8. Below is a list of factors that you may consider when deciding on the genetic testing that
you will offer a patient. Please rank each of the factors according to how often you
consider those factors. [Likert scale: often an important factor, sometimes an important
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I do not know

Ability to
include
parental
testing

Wide scope

Availability to
patients with
no/limited
insurance

Likelihood of
incidental
findings

Detection
rate

Test validity

Easy to
interpret
results

Low Cost

Quick
Turnaround
Time

factor, rarely an important factor, never an important factor. Also able to select “I am
not sure how I weigh this factor”]
a. Turnaround time
b. Patient cost and/or insurance coverage
c. Ability to interpret results
d. Test validity
e. Detection rate for suspected condition
f. Likelihood of incidental findings
g. Your confidence in a particular pre-testing clinical diagnosis
h. Patient preference
i. Ease of ordering
9. Which of the following factors have you ever considered to be the most important
consideration when deciding on the genetic testing you will offer a patient? [Select as
many as apply]
a. Turnaround time
b. Patient cost and/or insurance coverage
c. Ability to interpret results
d. Test validity
e. Detection rate for suspected condition
f. Likelihood of incidental findings
g. Your confidence in a particular pre-testing clinical diagnosis
h. Patient preference
i. Ease of ordering
10. Matrix: What do you consider to be the most significant advantage of ordering a _____?

WES
CMA
Panel
Single Gene
11. Matrix: What do you consider to be the most significant disadvantage of ordering a
_____?
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I do not know

Limited scope

Unavailability
to patients
with
no/limited
insurance

Likelihood of
incidental
findings

Detection
rate

Test validity

Difficult to
interpret
results

High Cost

Slow
Turnaround
Time

WES
CMA
Panel
Single Gene

I don’t know/it
depends

Karyotype

Single Gene
Sequencing

Panel Gene
Sequencing

WES

Fragile X
Analysis

CMA

I would not
order any
testing

Section 4

Autism with
intellectual disability
Autism without
intellectual disability
Seizures
Intellectual Disability
Behavioral Problems
Epilepsy
12. Why did you choose the testing strategy that you did for Autism with Intellectual
Disability? (ex: follows professional recommendations, save cost to patient, likely to
detect most common etiologies, took a guess, etc.) [Free response]
13. Why did you choose the testing strategy that you did for Autism without Intellectual
Disability? [Free response]
14. Why did you choose the testing strategy that you did for seizures? [Free response]
Section 5
1. How would you rate your knowledge of…? (Likert Scale 1-10)
a. Molecular genetics
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b. Neurological genetic conditions
c. Genetic testing guidelines for neurological conditions
2. Do you believe you would significantly benefit from more training on? [Yes/No/Unsure}
a. When to order genetic testing
b. How to interpret results
c. Counseling patients about genetic testing options
d. Explaining genetic test results to patients
3. The following question will assess your confidence about various elements of ordering
genetic tests. [Likert Scale: Very unconfident, somewhat unconfident, neither confident
nor unconfident, somewhat confident, very confident]
a. Knowing when to order genetic tests
b. Choosing the most appropriate test for a patient
c. Interpreting test results, including variants of uncertain significance
d. Explaining genetic test results to patients in a manner that is scientifically
accurate and patient-friendly
e. Handling the emotions that may arise during a genetic testing results disclosure
f. Ordering tests in a manner that maximizes the diagnostic power of my testing
plan while minimizing cost
4. Do you believe that genetic testing is underutilized in the field of neurology in general?
a. Strongly underutilized
b. Somewhat underutilized
c. Utilized the right amount
d. Somewhat overutilized
e. Strongly overutilized
f. I’m not sure
Section 6 (Demographics)
1. What is your gender identity?
a. Man
b. Woman
c. Other ______
2. What is your age? [Text Entry]
3. How many years have you been working in your current specialty? Enter 0 if less than 1
year. [Text Entry]
4. In what state is your primary practice located? [Select state from dropdown menu]
5. What is the number of active patients at your practice?
a. Less than 200
b. 201-500
22

c. 501-1000
d. 1001-3000
e. More than 3000
f. I’m not sure
6. Approximately what proportion of the patients you see are… [Number entry]
a. Privately insured
b. Insured by Medicaid
c. Insured by the military (ex: Tricare)
d. Uninsured/Self-pay
Thank you for participating in this survey. If you wish to be entered for a chance to win one of
two $50 Amazon gift cards, please follow the link and enter your email into the form. Your
email will not be associated with your responses. [Link]
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